Vanda Pharmaceuticals Inc Receivables Turnover Ratio (VNDA), from the second quarter 2026 to the second quarter 2025 current and historic results, rankings and more - CSIMarket
CSIMarket
 


Vanda Pharmaceuticals Inc   (NASDAQ: VNDA)
 

Vanda Pharmaceuticals Inc Accounts Receivables Turnover Ratio from the second quarter 2026 to the second quarter 2025

Quarterly Results, Trends, Rankings, Statistics


Vanda Pharmaceuticals Inc 's ability to collect accounts receivable sequentially worsen to 3.89, pointing to a challenging and on top of that deteriorating business climate for the Major Pharmaceutical Preparations industry. Vanda Pharmaceuticals Inc 's Accounts Receivable average collection period in the Jun 30 2026 quarter, has increased to 94 days, from 87 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 442 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2026 from 2088 to 2818.

What is Receivable Turnover Ratio?
What is Vanda Pharmaceuticals Inc Selling?


What is Receivable Turnover Ratio?





VNDA Receivables Turnover Ratio (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Receivable Change 32.67 % 27.52 % 15.87 % 18.22 % 7.47 %
Y / Y Revenue Change -3.92 % 3.35 % 7.58 % 18.06 % 4.19 %
Receivable Turnover Ratio (TTM) 3.89 4.21 4.44 4.53 4.54
VNDA's Total Ranking # 2818 # 2088 # 2153 # 2351 # 2333
Accounts Receivable average collection period days 94 87 82 81 80
Seq. Receivable Change 4.95 % 4.22 % 7.99 % 12.33 % 0.87 %
Seq. Revenue Change -2.3 % -9.61 % 1.7 % 6.97 % 5.09 %


Receivable Turnover Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 136
Healthcare Sector # 443
Overall Market # 2818

Receivable Turnover Ratio Statistics
High Average Low
22.46 9.84 3.89
(Jun 30 2013)   (Jun 30 2026)






Financial Statements
Vanda Pharmaceuticals Inc 's Accounts Receivable $ 60 Millions Visit VNDA's Balance sheet
Vanda Pharmaceuticals Inc 's Sales TTM $ 216 Millions Visit VNDA's Income Statement
Sources of VNDA's Revenues Visit VNDA's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
VNDA's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
VNDA's Growth Rates VNDA's Roa VNDA's Inventory Turnover Ratio VNDA's Dividend Comparisons
VNDA's Profitability Ratios VNDA's Roi VNDA's Asset Turnover Ratio VNDA's Dividend Growth
VNDA's Valuation Ratios VNDA's Roe VNDA's Financial Strength Ratios VNDA's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Jun 30 2026 Receivable at quarter ending Jun 30 2026
United Therapeutics Corporation  9.93 $ 3,154.500  Millions$ 317.550  Millions
Utah Medical Products Inc  9.88 $ 35.679  Millions$ 3.612  Millions
Biolife Solutions Inc   9.67 $ 102.718  Millions$ 10.626  Millions
The Oncology Institute Inc   9.66 $ 587.244  Millions$ 60.780  Millions
Sharps Technology Inc   9.65 $ 1.960  Millions$ 0.203  Millions
Encompass Health Corporation  9.57 $ 6,206.100  Millions$ 648.325  Millions
Septerna Inc   9.42 $ 98.882  Millions$ 10.501  Millions
Biofrontera Inc   9.33 $ 45.956  Millions$ 4.928  Millions
Enanta Pharmaceuticals Inc  9.29 $ 65.258  Millions$ 7.027  Millions
The Pennant Group Inc   9.27 $ 1,101.710  Millions$ 118.798  Millions
Crinetics Pharmaceuticals Inc   9.25 $ 42.156  Millions$ 4.558  Millions
Neuronetics Inc   9.24 $ 154.594  Millions$ 16.732  Millions
Myomo Inc   9.24 $ 44.242  Millions$ 4.790  Millions
Harmony Biosciences Holdings inc   9.22 $ 960.191  Millions$ 104.164  Millions
Bioaffinity Technologies Inc   9.18 $ 5.901  Millions$ 0.643  Millions
Pavmed Inc   9.16 $ 0.126  Millions$ 0.014  Millions
Clene Inc   9.16 $ 0.197  Millions$ 0.022  Millions
Ardent Health Inc   9.16 $ 6,405.940  Millions$ 699.363  Millions
Lexicon Pharmaceuticals Inc   9.14 $ 41.469  Millions$ 4.535  Millions
Novavax inc   9.06 $ 413.796  Millions$ 45.668  Millions
Nuvation Bio Inc   9.05 $ 169.551  Millions$ 18.737  Millions
Cue Biopharma Inc   9.04 $ 37.654  Millions$ 4.165  Millions
Sunshine Biopharma Inc   9.03 $ 35.347  Millions$ 3.916  Millions
Biocryst Pharmaceuticals Inc   9.00 $ 940.613  Millions$ 104.543  Millions
Edwards Lifesciences Corporation  8.99 $ 6,512.500  Millions$ 724.750  Millions
Cannapharmarx Inc   8.86 $ 1.699  Millions$ 0.192  Millions
Grail Inc   8.85 $ 165.263  Millions$ 18.670  Millions
Guardant Health Inc   8.84 $ 1,183.105  Millions$ 133.772  Millions
Zomedica Corp   8.84 $ 35.903  Millions$ 4.063  Millions
Scientific Industries Inc   8.83 $ 5.728  Millions$ 0.649  Millions

Date modified: 2026-10-05T11:03:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.